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The complete amino acid sequence of a mammalian acetylcholinesterase from fetal bovine serum (FBS ACHE) is presented. This enzyme has a 
high degree of sequence identity with other cholinesterases, liver carboxyesterases, esterase-6, lysophospholipase, and thyroglobulin. The locations 
of 191 amino acids in 10 regions of the FBS enzyme were compared with corresponding sequences of Torpedo, human, and Drosophila AChEs 
and human serum butyrylcholinesterase (BChE). In one region there is a marked ifference in both the number of amino acids and their sequence 
between mammalian AChE and other AChEs and the human serum BChE. The amino acid sequence of FBS AChE showed overall homologies 
of 90% with human ACHE, 60% with T. californica ACHE, 50% with human serum BChE, and 39% with Drosophila AChE in these regions. 
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1. INTRODUCTION 
Fetal bovine serum (FBS) contains relatively abun- 
dant amounts (0.3 mg/liter) of true acetylcholinesterase 
(EC 3.1.1.7; ACHE) and thus is a good source for ob- 
taining large quantities of purified mammalian AChE 
with relative ase [1,2]. We have attempted in the past 
four years to (a) develop a procedure to obtain large 
amounts of a mammalian AChE in purified form, (b) 
elucidate its primary structure, and (c) explore the 
possibility of using this enzyme as a pretreatment drug 
for protection against highly toxic organophosphate 
anti-ChEs [3,4]. For determination f chemical struc- 
ture and for demonstrating in vivo efficacy of AChE to 
sequester o ganophosphate nti-ChEs before they reach 
physiological targets, large quantities of purified en- 
zyme are required. Using procainamide Sepharose 4B 
gel as an affinity ligand, we have developed a simplified 
batch extraction procedure for purification of large 
quantities (up to 100 mg) of purified FBS AChE [5]. 
The use of AChE as an in vivo scavenger for 
organophosphate nti-ChEs requires that it be (a) im- 
munocompatible, (b) physiologically compatible with 
the species of animal, (c) not degraded or cleared rapid- 
ly (long half life), and (d) readily available in sufficient 
quantities, ince slightly more than one mole of enzyme 
will be needed to sequester one mole of organo- 
phosphate. 
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Primary structures of the catalytic subunit of AChE 
isolated from Torpedo californica, Torpedo marmorata 
and Drosophila melanogaster, and butyrylcholinester- 
ase (EC 3.1.1.8, BChE) isolated from human serum 
have recently been reported [6-11], as have partial se- 
quences of AChEs isolated from human erythrocytes 
[12,13], human brain [14], and bovine brain [15]. Phar- 
macological studies and enzyme kinetic studies with 
these enzymes, including multiple molecular forms, 
have demonstrated that they possess similar catalytic 
properties. The similarities and any differences in their 
catalytic functions hould be reflected in the correspon- 
ding similarities and differences in the structural do- 
mains of their catalytic subunit(s). The esteratic regions 
of several cholinesterases share a high degree of amino 
acid sequence homology [6], while some other regions 
are markedly dissimilar. 
In this report we present the complete amino acid se- 
quence of fetal bovine serum ACHE, the first mam- 
malian AChE to be sequenced. We have also compared 
the amino acid sequences of several regions in the 
catalytic subunit of FBS AChE with reported sequences 
in the corresponding regions of other cholinesterases. 
2. MATERIALS AND METHODS 
Acetylcholinesterase from fetal bovine serum (FBS) was purified as 
previously described [5]. The specific activity of purified enzyme was 
400 U/nmol, and 1 mg of enzyme contained 14 nmol of active site 
protein. Cyanogen bromide-cleaved peptides of the catalytic subunit 
of FBS AChE (approximately 200 nmol) were obtained by labeling the 
active site serine with [3H]diisopropylphosphofluoridate (DFP), 
followed by denaturation with 7 M guanidine-HCl, reduction with 
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dithiothreitol, and alkylation with [14C]N-methylmaleimide to label 
the reduced cysteine residues. The sample was exhaustively dialyzed 
against 10 mM NH4HCO3, lyophilized, resuspended (10 mg/ml) in 
80o70 formic acid, and digested with cyanogen bromide. The cleaved 
peptides were separated first on a Sephadex G-100 (superfine) column 
(1.2 x 50 cm) in 1.0% HOAC, followed by HPLC on ttBondapack 
C4 and/or C~s columns using TFA/acetonitrile or phosphate/ 
acetonitrile solvent gradients. The amino acid sequences of purified 
peptides were determined using a gas phase peptide/protein sequencer 
(ABI model 477A). PTH derivatives were identified on-line with 
HPLC (ABI model 120A). 
Trypsin-digested peptides of FBS-AChE were obtained by digesting 
denatured, reduced, and alkylated enzyme before lyophilization, as 
described above, with 1070 CPTK trypsin (w/w) in 50 mM NI-I4HCO3, 
pH 8.2, for 16-20 h. The peptides were separated on a Sephadex G-75 
column (1.2 × 50 cm) followed by HPLC on/zBondapack C4 and Cls 
columns using TFA/acetonitrile solvent gradients. 
The Torpedo californica AChE sequence is from Schumacher tal. 
[7]. The Torpedo marmorata sequence used here for comparison was 
reported by Bon et al. [15]. The amino acid sequence ofhuman serum 
BChE was obtained from published reports by Lockridge t al. [10]. 
The sequence of AChE from Drosophila melanogaster was done by 
Hall and Spierer [9]. The partial amino acid sequences of human 
AChEs shown here were determined by Soreq and Prody (human 
brain) [14l, Chhajlani et al. (human erythrocyte) [13], and Haas and 
Rosenberry (human erythrocyte) [12]. 
3. RESULTS AND DISCUSSION 
Fig. 1 describes the complete amino acid sequence of  
the catalytic subunit o f  FBS ACHE, which consists o f  
583 amino acids. For comparison, the amino acid se- 
quence of  Torpedo californica AChE is shown, as well 
as the strategy of  the sequence determination. Gapping 
is introduced in these sequences to maximize amino acid 
sequence homology: at amino acid 113 in Torpedo 
AChE (to accommodate one extra amino acid in FBS 
ACHE), at 258-261 in Torpedo (to accommodate four 
extra amino acids in FBS ACHE), at 495 in Torpedo (to 
accommodate one extra amino acid in FBS), and at 575 
(to accommodate one additional amino acid in human 
serum BChE, sequence not shown here). The calculated 
molecular mass for the FBS enzyme is 64 238, and ther~ 
are five apparent N-linked glycosylation sites (under. 
lined in the figure). The amino acid sequence of  the 
amino-terminus region was obtained by subjecting the 
intact protein to direct sequence analysis. The analysis 
of  nearly all of  the trypsin-digested peptides and the 
partial analysis of  CNBr-cleaved peptides were per- 
formed several times. Most of  the overlaps could be ob- 
tained by these analyses. One CNBr fragment consisted 
of  232 amino acids. The overlaps in this region were ob- 
tained by digesting the peptide with trypsin, separating 
the fragments, and analyzing each of  these tryptic pep- 
tides. The rest of  the overlaps were determined by com- 
parison of  the amino acid sequence of this AChE with 
the Torpedo AChE sequence. 
The FBS-AChE sequence shares an overall sequence 
identity of  90°70 with mouse AChE (personal com- 
munication, P. Taylor) and 60°70 with T. californica 
AChE [7]. In the small disulfide loop located between 
amino acids 257 and 272, there are four additional 
residues in the FBS and murine enzymes. FBS AChE 
also has a relatively high degree of  identity (52070) with 
butyrylcholinesterase from human serum [10] and 
human fetal tissue BChE [14], but somewhat less identi- 
ty (36%) with Drosophila AChE [9], rabbit and rat liver 
carboxyesterases [16] (33°7o and 35%, respectively), 
Drosophila esterase-6 [17] (29%), bovine thyroglobulin 
[18] (32%), and rat lysophospholipase [19] (32070). 
The amino terminus sequences of  several ChEs were 
compared by Bon et al. [15]. Fig. 2 updates their data 
for the first 12 amino acids with the addition of  the FBS 
AChE sequence for this region. The amino acid se- 
quences of  multiple molecular forms of  enzyme from 
the same source appear to be identical, although little 
homology appears among the ChEs isolated from 
various other species. The sequences of  AChEs from 
the two species of  Torpedo differ at position 5 
(His/Asp,  FBS AChE numbering) and at 12 other loca- 
tions in the molecule (not shown). In the sequences 
compared here, T. marmorata differs f rom T. califor- 
nica at positions 171,199, and 517 (M vs V, L vs I, I vs 
M, respectively, FBS AChE numbering system). 
Since multiple molecular forms of  AChE isolated 
f rom various species possess similar catalytic proper- 
ties, the active site serine-containing region (Ser-203) 
might be expected to have structural similarities. This 
was shown to be true by MacPhee-Quigley et al. [6], 
who compared the amino acid sequences of  Torpedo 
AChE with human serum BChE in this region, and 
Soreq and Prody [14], who added human brain AChE 
to the comparison. Similarities are now further revealed 
with our elucidation of  the amino acid sequence of  
mammal ian AChE from fetal bovine serum, as shown 
in Fig. 3C. There is complete identity among 21 amino 
acids between bovine and human AChEs,  and matching 
of  17 of  21 with human serum BChE, 16 of  21 with 
Torpedo AChE and 12 of  21 with Drosophila AChE 
The sequence PXXXTXFGESAGXXSV is common t, 
Fig. 1. Amino acid sequence ofFBS AChE and strategy of sequence determination. The amino acid sequence was determined by automated Edman 
degradation of (i) denatured, reduced, and alkylated intact enzyme (39 amino acid residues from amino terminus end), (ii) complete sequence of
4 CNBr-cleaved peptides (1,2,7, and 9), (iii) partial sequence of the remaining 5CNBr-cleaved peptides, (iv) complete sequence of44 tryptic pep- 
tides, and (v) partial sequence of one tryptic peptide (T14). CNBr peptide 6was further digested with trypsin, the peptides were fractionated and 
sequenced (Ta-Ts). Cysteine residues were identified by ~4C label. The disulfide loops shown are for Torpedo ACHE. The active site serine (@) 
was identified by 3H-labeling. The asterisk over Asp-95 and the pound sign over His-447 denote residues which, along with Ser-203, may be revolved 
in charge relay. The presumed N-linked glycosylation sites in Torpedo and FBS AChE are underlined. Gaps have been introduced into the Torpedo 
sequence to accommodate additional amino acids in the FBS sequence; gapping has been introduced into both sequences at position 575 to accom- 
modate an extra residue in human serum BChE (not shown here) [10]. 
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Torpedo AChE 
DD HS E LLVNTKSGKVMGTRVPVL  S S H I SAF LGI PFAEPPVGNM~RFRRP E P KKPW SGVWNAS TYPNNCQQYVD EQFPGF SG S EMWNPNREMS EDC Ly LN IWVP S pRp KS TT -VMVW I yG 
FBS-AChE 
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EGP EDP E LLVMVRGGE LRG LRLMAP RGPVSAF LG I PFAE 
I c i l i a - l - -  I c : lBn-2 I I csax-3 -  I I c'mB]t-4 I 
EGPEDPELLVM APRGPVSAFLGIPFAEPPVGPRRFLPPEPKRPWPGVL ~ WNPNRELSEDCLYLNVWTPypRP SSPT 
VRGGELRGLRLM 
IT1 I IT2- -1131 IT4--1 ITS I C lTT - - I  IT8 I IT9 I IT10 I 
EGPEDPELLVMVR GLR GPVSAFLGIPFAEPPVGPR FLPPEPK ELSEDCLYLNVWTPYPR 
GGELR LMAPR RPWPGVLNATAFQ SVCY QYUDT LY PGF EGTEMWNPNR PSSPTPVLVWIYG 
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Torpedo AChE 
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FLVQAEGTVLVSMNYR EAPGNVGLLDQR GLFHR 
GGFYSGAS SLDVYDGR VGAFGFLALPGSR LALQSVQENVAAFGGD P T SVT LFGE SAGAASVGMH L ~ AVLQSGAPNGPWATVG 
Tryps in  d igested  pept ides  of  CNBR-6  ~ ]TL I ITD--I ITo I 
HLLSPPSR AVLQSGAPNGPWATVG 
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VGEAR LVGCPPGGAGGNDTELVACLR VLPQEHVFR DEGSYFLVYGAPGFSK AQFL 
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ATLLAR ARPAQDLVDHEWR FSFVPWDGDFLSDTPEAL INAGDFVGLQVLVGVVK DNESL ISR 
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FBS-AChE 
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FBS AChe" EGPEDPELLVMV 
Bovine brain AChe b m/~PEDPELLVMV 
Human erythrocyte AChe c E/BG~ED~ 
T. marmorata AChe a ~jSELLV~ 
~~LbV~ , .  ca, ,orn,ca AChe" 
Drosophila AChe f 
Human serum BuChE Q ~ ~  
Fig. 2. Comparison fthe first 12 amino acids of the N-terminal se- 
quence of the catalytic subunit of FBS AChE with cholinesterases 
from other species and sources. Numbering corresponds to the amino 
acid sequence ofFBS ACHE; non-matching amino acids are shaded; 
the identity of the first amino acids in (b) and (c) has not been resolv- 
ed. aFBS AChE sequence r ported here; hsequence from bovine brain 
AChE obtained by Bon et al. [15]; %equence ofhuman erythrocyte 
AChE from Haas and Rosenberry [12]; asequence d termined byBon 
et al. for T. marmorata AChE [15]; %equence r ported for T. califor- 
nica by MacPhee-Quigley t al. [6] and Schumacher t al. [7]; fse- 
quence for Drosophila AChE by Hall and Spierer [9]; and ~sequence 
of human serum BChE by Lockridge t al. [10l. 
A: 
isI ~6J 
FBS AChe ° YRVGAFGFLAL  
Human brain AChe h YRVGAFGFLAL  
t. californica AChe ° YRVGAFGFLAL  
Drosophila AChE ~ YRVGAFGFLmL 
Human serum BuChE ° YRVGAIGFLAL 
B: 
~)o leo 
FBS AChe m NVGLLDQRLAL  
Human brain AChe h NVGLLDORLAL  
T. cal i fornica AChe ° NVGLLDQ~AL 
Drosophila AChe f NVGLIIDQIWLA| 
Human serum BuChE e NfGL~DQmLAE 
C: FBS AChe" DPTSVTLFGESAGAASVGMHL 
Human brain AChe h DPTSVTLFGESAGAASVGMHL 
t. californica AChe" DP~VT|FGESAG|ASVGMH| 
Drosophila AChe' IIPIIilRTLFGESAGIlUSVIIImiL 
Human serum BuChE Q IIPIISVTLFGESAGAASVlUJIHL 
all 5 cholinesterases. It should be pointed out that the 
folding pattern of this active site domain may be pivotal 
in conferring on these molecules the specificity of 
catalytic function. Using polyclonal and monoclonal 
antibodies it has recently been shown that this region is 
located in a pocket-like conformation [20]. 
Soreq and Prody [14] have reported partial amino 
acid sequences, deduced from a cDNA clone of fetal 
human brain ACHE, which represent 4 regions of the 
molecule which are potential candidates for catalytic 
sites. We have compared the amino acid sequence of 
FBS AChE with the sequences of five other ChEs in the 
same regions (Fig. 3A-C,G). Additionally, Soreq and 
Prody have suggested residue combinations for the 
charge relay system [14]. Asp-170 (Fig. 3B, Asp-175 in 
the FBS AChE numbering scheme) is central to all their 
combinations. The sequence in this region is highly con- 
served, and there is complete homology between human 
and bovine AChEs. However, based on results of the 
binding of inhibitory monoclonal antibody AE-2 to 
FBS ACHE, elucidation of its epitope, location, and the 
sequence homology in the region surrounding Asp-95 
[21], we feel that this amino acid, Asp-95, is a better 
candidate than Asp-170. Fig. 3G shows the amino acid 
sequence following His-432 and around His-447, both 
of which are conserved in all ChEs, and which are sug- 
gested by Soreq and Prody to be involved (His-423 and 
His-438 in their numbering scheme). We believe that the 
higher degree of sequence homology surrounding 
His-447 makes this amino acid a more likely candidate 
for involvement than His-432. Finally, the sequence 
presented in Fig. 3A includes Arg-152, which is propos- 
ed by Soreq and Prody as an alternate to histidine 
residues (Fig. 3G) in the charge relay system. Our pro- 
posal is that since both His-447 and Asp-95 are located 
in disulfide loops [6] and since Asp-95 is located next to 
Cys-96, which may affect its net charge, His-447 and 
Asp-95 are the most likely candidates for involvement 
with Ser-203 in the charge relay system. 
D: FBS AChe" ~VLQSGAPNGPWATVGVG' 
Human erythrocyte AChe ~ AVLQSGAPNGPWATVGII(3_ 
T. cal i fornics AChe" AJiLOSGIIPN|PWAIIV~ 
Drosophila AChe f I l I I J IQSGmN|P~ 
Human serum SuChE ~ ASLQSG~IIPWAWlII I lt  
E: FBS AChe ° 
Human erythrocyte AChe i 
T. californica AChe° 
Drosophila AChe f 
Human serum BuChE g 
~RPAQDLVDHEWRVLPQEHV~ 
|RPXO|LVXHEUlVLPQEUVF 
  F vlI INI 
F: FBS AChe • 
Human erythrocyte AChe i 
T. californica AChe e 
Drosophila AChe ~ 
Human serum BuChE o 
~GVPQASDLAAEAVVLHYTDWLHPEDP 
VGVPO|SDLAAEAVVL|YTDWLXPXDP 
MVP|A |DLDAVlL |YTDW~ 
~ i E I Y T a W ~ i  
~P~S~E~HYTDWHP 
4~ 
G: FBS ACHE" ~RASTLSWPLWMGVPHGYEIEFIFG 
Human brain AChe" HRASTLSW--WMGVPHGYEIEF~FG 
Human erythrocyte AChe i XXTLIIIIPLXMGVPXGY 
r. cal i fornics AChe" HRASILIWPIWMGVIHGYEIEF|FG 
Drosophila AChe f HR|S~ilI~W~WMGVIIHGalEIEIUlFG 
Human serum BuChE ~ HRISLIWPIWMGV~GYEIEF,~FG 
H: FBS AChe" APQWPPYTAGAOQYVSLNLRPLGV 
Human erythrocyte AChe i ~WPE_Y_YTAGAOOYVSLIILRPL~IV 
T. ca]ifornica AChe" ~ P ~  
Drosophi la AChE f 
Human serum SuChE ° ~ W P ~ Q I I Y I L N ~  
Fig. 3. Comparison famino acid sequences in various regions of FBS 
AChE with other cholinesterases. Sources of sequences are as noted 
for Fig. 2; amino acids are numbered according toFBS ACHE. (A) 
hsequence ofhuman brain ACHE, Arg-147 region as determined by
Soreq and Prody [14]. (B) hAsp-170 region in [14]. (C) The gapping 
introduced in (h) between sites 6 and 7 by Soreq and Prody [14] to 
align this region with serine hydrolases has been eliminated; the active 
site serine is marked with an asterisk. (D) Sequence for human 
erythrocyte AChE (i) is reported by Chhajlani et al. [13]. (E,F) Xs 
denote unidentified amino acids; gapping is introduced into the 
Drosophila sequence for alignment inthese regions. (G) hHis-423 and 
His-438 regions are merged with gapping between amino acids 439 
and 442 for alignment with FBS ACHE. 
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F~S ACHE" -I"VGCPPGGAGGNDTELVACLR 
Z. californica AChE~ BL- IC I  . . . .  D IEL~CLR 
Drosophila AChE - -~ IC~jRBIAml I~TU-~.A .  CIIR 
Human serum BuChE ~ -L~GC~ . . . .  INMTEI I ICLR 
Fig. 4. The comparison ofan amino acid sequence of FBS AChE with 
other cholinesterases in the region of a small disulfide loop (dashed 
line). 
Chhaj lan i  et al. [13] reported the amino acid se- 
quences o f  5 tryptic peptides of  human erythrocyte 
ACHE, shown in Fig. 3D-H.  These authors observed 
little or no homology  when compar ing the sequences 
with Torpedo AChE and human serum BChE. 
However ,  when these sequences are compared  to other 
mammal ian  AChEs ,  approx imate ly  88070 sequence 
ident i ty is observed (85 o f  97 amino acid residues). 
F inal ly,  the compar ison of  amino acid sequences of  
FBS AChE with T. californica nd Drosophila AChEs  
and human serum BChE in the region o f  a small 
disulf ide loop (amino acids 254-275, Fig. 4) shows that 
FBS AChE has four extra amino acids in the loop.  The 
presence o f  these addit ional  amino acids in the loop in 
mammal ian  AChEs  would result in a di f ferent confor-  
mat ion  in this region. 
Among the sequences compared  here, there is 90% 
amino  acid sequence homology  between FBS AChE 
and human AChEs ,  60°7o with T. californica ACHE, 
39% with Drosophila ACHE, and 50°70 with human 
serum BChE,  values equivalent to those for the 
homologies  of  the catalyt ic subunits.  In general we con- 
clude that,  not unexpectedly,  mammal ian  AChEs  ap- 
pear  to have structures more in common with each 
other  than with Torpedo AChE or human serum BChE. 
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